VEGF/VEGFR Antibodies & Proteins: Reagents for Angiogenesis Research

Tumor angiogenesis — the growth of new blood vessels from existing vasculature — is a hallmark of cancer driven primarily by the VEGF/VEGFR signaling axis. VEGF is both a key growth factor in the cytokine/growth factor family and a critical component of the tumor microenvironment.

Target Biology and Clinical Relevance

VEGF-A is the principal pro-angiogenic factor secreted by tumor and stromal cells. It binds VEGFR-1 (FLT1) and VEGFR-2 (KDR), with VEGFR-2 being the primary mediator of angiogenic signaling in endothelial cells.

Bevacizumab (anti-VEGF-A) and ramucirumab (anti-VEGFR-2) are approved for multiple tumor types including CRC, NSCLC, RCC, HCC, and GBM. Research biosimilar versions enable affordable PK/ADA assay development and preclinical combination studies.

Anti-VEGF and anti-VEGFR antibodies are used in IHC for tumor vasculature assessment (CD31/VEGFR-2 co-staining), ELISA for serum VEGF quantification, and functional neutralization assays (endothelial tube formation, migration, proliferation inhibition).

Recombinant VEGF-A, VEGF-B, VEGF-C, and VEGF-D proteins are available for endothelial cell stimulation assays, receptor binding studies, and as ELISA standards. For reconstitution and handling best practices, see our Recombinant Protein Handling Guide. For a broader view of all oncology research areas, see our Cancer Research Reagents hub.

abinScience Product Coverage

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-1437. doi: 10.1038/nm.3394

3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

All products are for research use only. For technical support, contact order@abinscience.com.